Induction  ||| S:0 E:10 ||| NNP
of  ||| S:10 E:13 ||| IN
endothelial  ||| S:13 E:25 ||| JJ
cell  ||| S:25 E:30 ||| NN
apoptosis  ||| S:30 E:40 ||| NN
by  ||| S:40 E:43 ||| IN
anti-alpha-enolase  ||| S:43 E:62 ||| JJ
antibody  ||| S:62 E:71 ||| NN
To  ||| S:71 E:74 ||| TO
assess  ||| S:74 E:81 ||| VB
the  ||| S:81 E:85 ||| DT
prevalence  ||| S:85 E:96 ||| NN
of  ||| S:96 E:99 ||| IN
anti-alpha-enolase  ||| S:99 E:118 ||| JJ
antibody  ||| S:118 E:127 ||| NN
in  ||| S:127 E:130 ||| IN
systemic  ||| S:130 E:139 ||| JJ
autoimmune  ||| S:139 E:150 ||| JJ
diseases  ||| S:150 E:159 ||| NNS
in  ||| S:159 E:162 ||| IN
Chinese  ||| S:162 E:170 ||| JJ
patients  ||| S:170 E:179 ||| NNS
and  ||| S:179 E:183 ||| CC
its  ||| S:183 E:187 ||| PRP$
role  ||| S:187 E:192 ||| NN
in  ||| S:192 E:195 ||| IN
endothelial  ||| S:195 E:207 ||| JJ
cell  ||| S:207 E:212 ||| NN
apoptosis ||| S:212 E:221 ||| NN
.  ||| S:221 E:223 ||| .
The  ||| S:223 E:227 ||| DT
reactivity  ||| S:227 E:238 ||| NN
of  ||| S:238 E:241 ||| IN
anti-alpha-enolase  ||| S:241 E:260 ||| JJ
antibody  ||| S:260 E:269 ||| NN
in  ||| S:269 E:272 ||| IN
a  ||| S:272 E:274 ||| DT
variety  ||| S:274 E:282 ||| NN
of  ||| S:282 E:285 ||| IN
autoimmune  ||| S:285 E:296 ||| JJ
disorders  ||| S:296 E:306 ||| NNS
in  ||| S:306 E:309 ||| IN
Chinese  ||| S:309 E:317 ||| JJ
patients  ||| S:317 E:326 ||| NNS
was  ||| S:326 E:330 ||| VBD
evaluated  ||| S:330 E:340 ||| VBN
by  ||| S:340 E:343 ||| IN
dot  ||| S:343 E:347 ||| JJ
blot  ||| S:347 E:352 ||| JJ
assay ||| S:352 E:357 ||| NN
.  ||| S:357 E:359 ||| .
Endothelial  ||| S:359 E:371 ||| JJ
cell  ||| S:371 E:376 ||| NN
apoptosis  ||| S:376 E:386 ||| NNS
was  ||| S:386 E:390 ||| VBD
investigated  ||| S:390 E:403 ||| VBN
by  ||| S:403 E:406 ||| IN
in  ||| S:406 E:409 ||| IN
vitro  ||| S:409 E:415 ||| JJ
incubation  ||| S:415 E:426 ||| NN
of  ||| S:426 E:429 ||| IN
endothelial  ||| S:429 E:441 ||| JJ
cells  ||| S:441 E:447 ||| NNS
with  ||| S:447 E:452 ||| IN
IgG  ||| S:452 E:456 ||| JJ
purified  ||| S:456 E:465 ||| NN
from  ||| S:465 E:470 ||| IN
anti-alpha-enolase  ||| S:470 E:489 ||| JJ
antibody-positive  ||| S:489 E:507 ||| JJ
sera ||| S:507 E:511 ||| NN
,  ||| S:511 E:513 ||| ,
with  ||| S:513 E:518 ||| IN
or  ||| S:518 E:521 ||| CC
without  ||| S:521 E:529 ||| IN
pre-incubation  ||| S:529 E:544 ||| JJ
with  ||| S:544 E:549 ||| IN
recombinant  ||| S:549 E:561 ||| JJ
alpha-enolase ||| S:561 E:574 ||| NN
.  ||| S:574 E:576 ||| .
Anti-alpha-enolase  ||| S:576 E:595 ||| JJ
antibody  ||| S:595 E:604 ||| NN
was  ||| S:604 E:608 ||| VBD
prevalent  ||| S:608 E:618 ||| VBN
in  ||| S:618 E:621 ||| IN
different  ||| S:621 E:631 ||| JJ
systemic  ||| S:631 E:640 ||| JJ
autoimmune  ||| S:640 E:651 ||| JJ
diseases  ||| S:651 E:660 ||| NNS
with  ||| S:660 E:665 ||| IN
relatively  ||| S:665 E:676 ||| RB
high  ||| S:676 E:681 ||| JJ
reactivity  ||| S:681 E:692 ||| NN
in  ||| S:692 E:695 ||| IN
Chinese  ||| S:695 E:703 ||| JJ
patients ||| S:703 E:711 ||| NNS
.  ||| S:711 E:713 ||| .
In  ||| S:713 E:716 ||| IN
vitro  ||| S:716 E:722 ||| JJ
incubation  ||| S:722 E:733 ||| NN
of  ||| S:733 E:736 ||| IN
endothelial  ||| S:736 E:748 ||| JJ
cells  ||| S:748 E:754 ||| NNS
with  ||| S:754 E:759 ||| IN
IgG  ||| S:759 E:763 ||| JJ
containing  ||| S:763 E:774 ||| VBG
anti-alpha-enolase  ||| S:774 E:793 ||| JJ
antibody  ||| S:793 E:802 ||| NN
induced  ||| S:802 E:810 ||| NN
apoptosis  ||| S:810 E:820 ||| NN
in  ||| S:820 E:823 ||| IN
a  ||| S:823 E:825 ||| DT
time-  ||| S:825 E:831 ||| JJ
and  ||| S:831 E:835 ||| CC
dose-dependent  ||| S:835 E:850 ||| JJ
manner ||| S:850 E:856 ||| NN
.  ||| S:856 E:858 ||| .
Apoptosis  ||| S:858 E:868 ||| NNP
was  ||| S:868 E:872 ||| VBD
partly  ||| S:872 E:879 ||| RB
inhibited  ||| S:879 E:889 ||| VBN
by  ||| S:889 E:892 ||| IN
pre-incubation  ||| S:892 E:907 ||| JJ
of  ||| S:907 E:910 ||| IN
the  ||| S:910 E:914 ||| DT
endothelial  ||| S:914 E:926 ||| JJ
cells  ||| S:926 E:932 ||| NNS
with  ||| S:932 E:937 ||| IN
recombinant  ||| S:937 E:949 ||| JJ
alpha-enolase ||| S:949 E:962 ||| NN
.  ||| S:962 E:964 ||| .
Our  ||| S:964 E:968 ||| PRP$
data  ||| S:968 E:973 ||| NNS
suggest  ||| S:973 E:981 ||| VBP
that  ||| S:981 E:986 ||| IN
alpha-enolase  ||| S:986 E:1000 ||| NNP
is  ||| S:1000 E:1003 ||| VBZ
a  ||| S:1003 E:1005 ||| DT
common  ||| S:1005 E:1012 ||| JJ
auto-antigen  ||| S:1012 E:1025 ||| NN
recognized  ||| S:1025 E:1036 ||| VBN
by  ||| S:1036 E:1039 ||| IN
anti-endothelial  ||| S:1039 E:1056 ||| JJ
cell  ||| S:1056 E:1061 ||| NN
antibodies  ||| S:1061 E:1072 ||| NNS
in  ||| S:1072 E:1075 ||| IN
connective  ||| S:1075 E:1086 ||| JJ
tissue  ||| S:1086 E:1093 ||| NN
disease ||| S:1093 E:1100 ||| NN
.  ||| S:1100 E:1102 ||| .
Interaction  ||| S:1102 E:1114 ||| NNP
between  ||| S:1114 E:1122 ||| IN
alpha-enolase  ||| S:1122 E:1136 ||| JJ
and  ||| S:1136 E:1140 ||| CC
its  ||| S:1140 E:1144 ||| PRP$
autoantibody  ||| S:1144 E:1157 ||| NN
plays  ||| S:1157 E:1163 ||| VBZ
a  ||| S:1163 E:1165 ||| DT
role  ||| S:1165 E:1170 ||| NN
in  ||| S:1170 E:1173 ||| IN
endothelial  ||| S:1173 E:1185 ||| JJ
cell  ||| S:1185 E:1190 ||| NN
apoptosis ||| S:1190 E:1199 ||| NN
.  ||| S:1199 E:1201 ||| .
Changes  ||| S:1201 E:1209 ||| NNS
other  ||| S:1209 E:1215 ||| JJ
than  ||| S:1215 E:1220 ||| IN
cell  ||| S:1220 E:1225 ||| NN
killing  ||| S:1225 E:1233 ||| NN
may  ||| S:1233 E:1237 ||| MD
contribute  ||| S:1237 E:1248 ||| VB
to  ||| S:1248 E:1251 ||| TO
the  ||| S:1251 E:1255 ||| DT
pathogenesis  ||| S:1255 E:1268 ||| NN
of  ||| S:1268 E:1271 ||| IN
endothelial  ||| S:1271 E:1283 ||| JJ
damage  ||| S:1283 E:1290 ||| NN
and  ||| S:1290 E:1294 ||| CC
microvascular  ||| S:1294 E:1308 ||| JJ
lesions ||| S:1308 E:1315 ||| NNS
.  ||| S:1315 E:1317 ||| .
